Transthyretin Amyloid Cardiomyopathy (ATTR-CM) – Market Access and Reimbursement Insights Report – 2025

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Access and Reimbursement Insights

Thelansis’s “Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Overview

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of systemic amyloidosis characterized by misfolded transthyretin (TTR) protein deposition in the myocardium. Another notable cause of cardiac amyloidosis is the accumulation of immunoglobulin light-chain (AL) aggregates. Although several amyloidogenic proteins may be deposited in various organs and tissues, myocardial involvement is rare. Symptoms of ATTR-CM can vary, and the condition is frequently misdiagnosed, with early stages resembling symptoms of other conditions such as hypertensive heart failure or hypertrophic cardiomyopathy. Some patients may be asymptomatic, while others may progress to end-stage heart failure. The disease is classified based on the sequence of the TTR gene, distinguishing between wtATTR-CM (no mutation) and hATTR-CM (presence of a mutation). In 2019, the FDA approved tafamidis and tafamidis meglumine for treating ATTR-CM. Both agents selectively bind to the transthyretin tetramer, preventing the destabilization of the transthyretin transport protein and the subsequent amyloid formation that leads to ATTR-CM.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
  • Coverage on plans
  • Market access restrictions
  • Rebates and contracting
  • Factors influencing formulary access
  • HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
  • Level of awareness
  • Anticipated coverage on plans
  • Factors that would improve market access
  • Pricing, etc.
• Impact on brand use
  • Key factors driving and limiting brand use
  • Best and worst performers on market access, etc.
• Evolving environment
  • Payer expectations from emerging therapies
  • New policies and their expected impact, etc.
  • Advise to drug manufacturers and developers

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)